

Supplementary Information

A supramolecular adduct of tegafur and syringic acid: The first tegafur-nutraceutical cocrystal with the perfected *in vitro* and *in vivo* characteristics as well as synergized anticancer activities

Yue-Ming Yu,^{a,+} Ming-Chao Yu,^{a,+} Ling-Yang Wang,^a Yan-Tuan Li,^{a,b,*} Zhi-Yong Wu,^{a,*} and Cui-Wei Yan^{a,*}

^a*School of Medicine and Pharmacy and College of Marine Life Science, Ocean University of China, Qingdao, Shandong 266003, PR China.*

^b*Laboratory for Marine Drugs and Bioproducts, Qingdao National Laboratory for Marine Science and Technology, 266003, PR China.*

* Correspondence to: Yan-Tuan Li, Zhi-Yong Wu and Cui-Wei Yan.

E-mail addresses: yantuanli@ouc.edu.cn (Yan-Tuan Li), wzy_ouc@163.com (Zhi-Yong Wu) cuiweiyang@ouc.edu.cn (Cui-Wei Yan).

⁺These authors contributed equally to this work.

*Correspondence to: Yan-Tuan Li, Zhi-Yong Wu and Cui-Wei Yan.

E-mail address: yantuanli@ouc.edu.cn; Zhi-Yong Wu, E-mail: wzy_ouc@163.com Cui-Wei Yan, E-mail: cuiweiyang@ouc.edu.cn.

Contents

Fig. S1. FT-IR spectra of TF-SYA compared with its starting materials.

Fig. S2. PXRD patterns of TF-SYA at buffers pH and simulated.

Fig. S3. IDR profiles of TF, SYA and TF-SYA.




Fig. S1. IR spectra of TF, SYA and TF-SYA.




Fig. S2. PXRD patterns of TF-SYA at buffers pH and simulated.




Fig. S3. IDR profiles of TF, SYA and TF-SYA at pH 1.2, 4.0, and 6.8.